JP2014530603A5 - - Google Patents

Download PDF

Info

Publication number
JP2014530603A5
JP2014530603A5 JP2014534726A JP2014534726A JP2014530603A5 JP 2014530603 A5 JP2014530603 A5 JP 2014530603A5 JP 2014534726 A JP2014534726 A JP 2014534726A JP 2014534726 A JP2014534726 A JP 2014534726A JP 2014530603 A5 JP2014530603 A5 JP 2014530603A5
Authority
JP
Japan
Prior art keywords
vivo method
hiv
cells
endogenous
transgene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014534726A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014530603A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2014530603A publication Critical patent/JP2014530603A/ja
Publication of JP2014530603A5 publication Critical patent/JP2014530603A5/ja
Pending legal-status Critical Current

Links

JP2014534726A 2011-10-06 2012-10-04 Hiv感染を制御するための方法および組成物 Pending JP2014530603A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161544101P 2011-10-06 2011-10-06
US61/544,101 2011-10-06

Publications (2)

Publication Number Publication Date
JP2014530603A JP2014530603A (ja) 2014-11-20
JP2014530603A5 true JP2014530603A5 (enExample) 2015-10-08

Family

ID=48044158

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014534726A Pending JP2014530603A (ja) 2011-10-06 2012-10-04 Hiv感染を制御するための方法および組成物

Country Status (7)

Country Link
US (2) US20130171732A1 (enExample)
EP (1) EP2764102A4 (enExample)
JP (1) JP2014530603A (enExample)
AU (1) AU2012318562A1 (enExample)
CA (1) CA2849920A1 (enExample)
HK (1) HK1200491A1 (enExample)
WO (1) WO2013052681A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3099582A1 (en) * 2011-10-27 2013-05-02 Sangamo Biosciences, Inc. Methods and compositions for modification of the hprt locus
WO2014093709A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Methods, models, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof
EP3031921B1 (en) 2012-12-12 2025-03-12 The Broad Institute, Inc. Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications
EP2931899A1 (en) 2012-12-12 2015-10-21 The Broad Institute, Inc. Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof
WO2014204724A1 (en) 2013-06-17 2014-12-24 The Broad Institute Inc. Delivery, engineering and optimization of tandem guide systems, methods and compositions for sequence manipulation
CN105492611A (zh) * 2013-06-17 2016-04-13 布罗德研究所有限公司 用于序列操纵的优化的crispr-cas双切口酶系统、方法以及组合物
EP3725885A1 (en) 2013-06-17 2020-10-21 The Broad Institute, Inc. Functional genomics using crispr-cas systems, compositions methods, screens and applications thereof
MX374532B (es) 2013-06-17 2025-03-06 Broad Inst Inc Suministro, uso y aplicaciones terapéuticas de los sistemas y composiciones crispr-cas, para actuar sobre trastornos y enfermedades utilizando componentes víricos.
RU2716420C2 (ru) 2013-06-17 2020-03-11 Те Брод Инститьют Инк. Доставка и применение систем crispr-cas, векторов и композиций для целенаправленного воздействия и терапии в печени
CN105683379A (zh) 2013-06-17 2016-06-15 布罗德研究所有限公司 用于对有丝分裂后细胞的疾病和障碍进行靶向和建模的系统、方法和组合物的递送、工程化和优化
CA2930877A1 (en) * 2013-11-18 2015-05-21 Crispr Therapeutics Ag Crispr-cas system materials and methods
EP3080259B1 (en) 2013-12-12 2023-02-01 The Broad Institute, Inc. Engineering of systems, methods and optimized guide compositions with new architectures for sequence manipulation
WO2015089364A1 (en) 2013-12-12 2015-06-18 The Broad Institute Inc. Crystal structure of a crispr-cas system, and uses thereof
EP3470089A1 (en) 2013-12-12 2019-04-17 The Broad Institute Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components
JP6712948B2 (ja) 2013-12-12 2020-06-24 ザ・ブロード・インスティテュート・インコーポレイテッド 組成物、及びヌクレオチドリピート障害におけるcrispr−cas系の使用方法
SG10201804975PA (en) 2013-12-12 2018-07-30 Broad Inst Inc Delivery, Use and Therapeutic Applications of the Crispr-Cas Systems and Compositions for HBV and Viral Diseases and Disorders
JP7103750B2 (ja) 2013-12-12 2022-07-20 ザ・ブロード・インスティテュート・インコーポレイテッド ゲノム編集のためのCRISPR-Cas系及び組成物の送達、使用及び治療適用
JP6793547B2 (ja) 2013-12-12 2020-12-02 ザ・ブロード・インスティテュート・インコーポレイテッド 最適化機能CRISPR−Cas系による配列操作のための系、方法および組成物
WO2016014837A1 (en) * 2014-07-25 2016-01-28 Sangamo Biosciences, Inc. Gene editing for hiv gene therapy
EP3889260A1 (en) 2014-12-12 2021-10-06 The Broad Institute, Inc. Protected guide rnas (pgrnas)
CA2970370A1 (en) 2014-12-24 2016-06-30 Massachusetts Institute Of Technology Crispr having or associated with destabilization domains
US10059940B2 (en) * 2015-01-27 2018-08-28 Minghong Zhong Chemically ligated RNAs for CRISPR/Cas9-lgRNA complexes as antiviral therapeutic agents
WO2016205759A1 (en) 2015-06-18 2016-12-22 The Broad Institute Inc. Engineering and optimization of systems, methods, enzymes and guide scaffolds of cas9 orthologs and variants for sequence manipulation
TWI906646B (zh) 2015-06-18 2025-12-01 美商博得學院股份有限公司 降低脫靶效應的crispr酶突變

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1352960A1 (en) * 2002-04-12 2003-10-15 Viruvation B.V. Antiviral therapy on the basis of RNA interference
US20070134796A1 (en) * 2005-07-26 2007-06-14 Sangamo Biosciences, Inc. Targeted integration and expression of exogenous nucleic acid sequences
WO2007014181A2 (en) * 2005-07-25 2007-02-01 Johns Hopkins University Site-specific modification of the human genome using custom-designed zinc finger nucleases
US20080003681A1 (en) * 2006-06-28 2008-01-03 Mahalaxmi Gita Bangera Methods for altering cellular susceptibility to infection
US8563314B2 (en) * 2007-09-27 2013-10-22 Sangamo Biosciences, Inc. Methods and compositions for modulating PD1
EP2303292A4 (en) * 2008-06-09 2013-01-02 New York Medical College COMPOSITIONS WITH CARDIAL STEM CELLS WITH OVEREXPRESSION OF SPECIFIC MICRORNAS AND METHOD FOR THEIR USE IN THE REPAIR OF THE CARED MYOCARDIC
EP2408921B1 (en) * 2009-03-20 2017-04-19 Sangamo BioSciences, Inc. Modification of cxcr4 using engineered zinc finger proteins
WO2011017315A2 (en) * 2009-08-03 2011-02-10 Recombinetics, Inc. Methods and compositions for targeted gene modification
CN102071219B (zh) * 2010-11-05 2014-03-12 冯小荣 改腺载体及其在艾滋病预防和治疗药物中的应用

Similar Documents

Publication Publication Date Title
JP2014530603A5 (enExample)
JP2016539627A5 (enExample)
JP7440027B2 (ja) 多能性幹細胞から免疫細胞療法用t細胞を誘導する方法
Sun et al. Advances in the techniques and methodologies of cancer gene therapy
Deering et al. Nucleic acid vaccines: prospects for non-viral delivery of mRNA vaccines
WO2016073955A3 (en) Cells lacking b2m surface expression and methods for allogeneic administration of such cells
US20230348932A1 (en) Scarless genome editing through two-step homology directed repair
Kallen et al. A development that may evolve into a revolution in medicine: mRNA as the basis for novel, nucleotide-based vaccines and drugs
Sinclair et al. The intimate relationship between human cytomegalovirus and the dendritic cell lineage
CY1122902T1 (el) Ιοσωματιδια αδενο-συσχετιζομενου ιου με καψιδιο παραλλαγματος και μεθοδοι χρησης εξ αυτων
US12485187B2 (en) Method for improving retroviral transduction and gene editing in hematopoietic stem cells using clyclosporin H and UM171
MX2024006041A (es) Celulas t modificadas y metodos para hacer y usar las mismas.
JP2018525979A5 (enExample)
AR092317A1 (es) Vectores virales para el tratamiento de distrofia retiniana
MX2021009554A (es) Produccion de virus en cultivos celulares.
JP2024519524A (ja) 疾患の処置のために有用なレンチウイルスベクター
WO2016010155A1 (ja) 抗原特異的t細胞受容体遺伝子を有する多能性幹細胞の製造方法
Maring et al. Myocardial regeneration via progenitor cell‐derived exosomes
Murugesan et al. Current approaches and potential challenges in the delivery of gene editing cargos into hematopoietic stem and progenitor cells
Younan et al. Genetically Modified Hematopoietic Stem Cell Transplantation for HIV-1–infected Patients: Can We Achieve a Cure?
WO2012159120A3 (en) Gene therapy based strategy for treating hiv
ES2536605B1 (es) Método de obtención de megacariocitos y plaquetas
Freitas et al. Advances in engineering myeloid cells for cell therapy applications
Wang et al. Engineering hematopoietic stem cells toward a functional cure of human immunodeficiency virus infection
WO2025052001A1 (en) Methods and compositions for improving immune response